news coming, page-5

“Exciting recent advancements
in antisense technology together with the pre-clinical work that we have already conducted on ATL1101
gives us encouragement that further development of the drug is definitely warranted. In addition, we have
had interactions with other parties interested in our technology giving us confidence that we are well
placed to find a suitable development partner or licensee for ATL1101. There has been a resurgence of
interest in the antisense technology platform as evidenced by the number of licensing transactions that
have been executed by our technology partner Isis Pharmaceuticals who is also preparing for approval and
launch of the world’s first systemically administered antisense drug. As noted in previous announcements
to the market, ANP also has active partnering and development interest in our own antisense programs
including ATL1103 and ATL1102. Accordingly we are enthusiastic about the prospects for the further
development of ATL1101. We look forward to providing the market with further updates on the progress of
these plans”.